Spots Global Cancer Trial Database for Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection
Official Title: A Multicenter, Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Cross-over Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection 20mg/10mL of Dr. Reddy's Laboratories Ltd, India, With That of Doxorubicin Hydrochloride Liposome Injection 20 mg/10mL , Manufactured by: Sun Pharmaceutical Ind. Ltd, India; in Ovarian Cancer Patients Whose Disease Has Progressed or Recurred After Platinum Based Chemotherapy and Who Are Already Receiving or Scheduled to Start Therapy With the Reference Listed Drug Under Fasting Condition.
Study ID: NCT02260544
Conditions
Interventions
Study Description
Brief Summary: Bioequivalence study is proposed to be carried out on patients of ovarian cancer, who are already receiving or who in the opinion of their treating physicians are candidates for Doxorubicin liposomal injection therapy .
Detailed Description: This study has sequential two stage design. Bioequivalence based on encapsulated doxorubicin will be tested at the end of stage 1. Power analysis will be performed for the primary pharmacokinetic parameters of free Doxorubicin and liposome encapsulated Doxorubicin, for all completed patients before bioequivalence evaluation. If observed power will be \>= 80% then two one-sided 90% CI will be calculated for bioequivalence assessment at stage I. If observed power will be \< 80% then bioequivalence will be evaluated at stage I. If bioequivalence met then study will be stopped and if bioequivalence not met, then required additional patients will be enrolled in stage II. Each patient will be randomized to one of the two treatment sequences ( RT or TR ) according to a randomization scheme prepared prior to the start of the trial. Serial blood samples for determination of free doxorubicin and liposomal encapsulated doxorubicin plasma concentration for PK analysis will be obtained in each cycle . Bioequivalence Criteria : The 94.12% confidence intervals for the ratio of geometric least squares means of ln-transformed pharmacokinetic parameters Cmax, AUC0-t and AUC0-inf should be within 80.00 to125.00% to conclude the test product is bioequivalent to the reference product.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
City Cancer Center, Vijaywada, Andhra Pradesh, India
Nirmal Hospital Pvt Ltd, Surat, Gujarat, India
Srinivasam Cancer Care Hospitals India Private Limited, Bangalore, Karnataka, India
Erode Cancer Center, Erode, Karnataka, India
Cancer Clinic and Nursing Home & Jasleen Hospital, Nagpur, Maharahtra, India
Curie Manavta Cancer Centre, Nashik, Maharashtra, India
Acharya HariHar Regional Cancer Centre, Cuttack, Orissa, India
Meenakshi Mission Hospital & Research Centre, Madurai, Tamil Nadu, India
Dr. G. Viswanathan Speciality Hospitals, Trichy, Tamil Nadu, India
Bibi General Hospital, Hyderabad, Telangana, India
MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad, Telangana, India
Contact Details
Name: Ashis Patnaik, MBBS, MD
Affiliation: Dr. Reddy's Laboratories Limited
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
